Foghorn Therapeutics pauses enrollment in cancer drug study (updated)
24/04/2023 12:46
(Adds details)
April 24 (Reuters) - Drug developer Foghorn Therapeutics
Inc FHTX.O said on Monday it has paused enrollment in an
early-stage study of the company's experimental drug for a rare
form of cancer due to safety concerns.
The company said the U.S. Food and Drug Administration has
also placed the study on partial hold in the United States,
while allowing patients currently enrolled and benefiting from
therapy to continue dosage of the drug, FHD-609.
One of the patients', who was receiving the second highest
dosage of the drug in the study, heart muscle was taking longer
than normal to contract between beats.
Foghorn said it was not planning to pursue a dose expansion
study independently.
The drug developer said it has also informed European health
regulators on the adverse event related to the clinical trial.
FHD-609 was undergoing early-stage study to treat patients
with a rare form of cancer in soft tissue called synovial
sarcoma and as a potential treatment for tumors arising from the
absence of the SMARCB1 gene.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika
Syamnath)
((Khushi.Mandowara@thomsonreuters.com;))